Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis. Alkermes derives revenues on net sales of its proprietary products: Vivitrol & Aristada, and manufacturing and/or royalty revenues on net sales of products commercialized by the company's partners. These include Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Ampyra/Fampyra and Bydureon. Interesting late-stage candidate in the company's pipeline include nemvaleukin alfa developed for treating advanced solid tumors. Its proprietary drugs are Vivitrol & Aristada.
| Revenue (Most Recent Fiscal Year) | $1.56B |
| Net Income (Most Recent Fiscal Year) | $367.07M |
| PE Ratio (Current Year Earnings Estimate) | 20.32 |
| PE Ratio (Trailing 12 Months) | 12.39 |
| PEG Ratio (Long Term Growth Estimate) | 1.65 |
| Price to Sales Ratio (Trailing 12 Months) | 2.96 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.74 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 10.18 |
| Pre-Tax Margin (Trailing 12 Months) | 27.27% |
| Net Margin (Trailing 12 Months) | 23.15% |
| Return on Equity (Trailing 12 Months) | 24.86% |
| Return on Assets (Trailing 12 Months) | 17.14% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.31 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.92 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.20 |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.85 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.52 |
| Earnings per Share (Most Recent Fiscal Year) | $2.37 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.08 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 164.90M |
| Free Float | 157.65M |
| Market Capitalization | $4.45B |
| Average Volume (Last 20 Days) | 1.97M |
| Beta (Past 60 Months) | 0.44 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.21% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |